Performance of the AmpliSeq NGS panel in thyroid nodules with indeterminate cytology
Different ancillary molecular tests have been marketed in the USA and are integrated into the management of thyroid nodules with indeterminate cytology. Unfortunately, none of these molecular tests are currently available in France and clinicians lack effective tools for the management of these nodules. The aim of this work was to assess the performance of a large general-cancer targeted NGS panel in a series of thyroid nodules with indeterminate cytology (i.e. Bethesda III and IV categories and, to some extent, the Bethesda V category), managed in a French university medical center referral for thyroid tumors.
Authors
- François Ansart (ORCID: https://orcid.org/0009-0007-5957-2950)
- Laurence Leenhardt (ORCID: https://orcid.org/0000-0003-4131-6813)
- Malanie Roy (ORCID: https://orcid.org/0000-0001-5838-0155)
- Florence Coulet (ORCID: https://orcid.org/0000-0002-5325-5272)
- Gabrielle Deniziaut
- Camille Buffet (ORCID: https://orcid.org/0000-0003-1389-4157)
- Wiame Potonnier
- C. Ghander
- Erell Guillerm
- Isabelle Brochériou
- Fabrice Mènégaux
- C. Bigorgne
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Sorbonne Université (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Laboratoire d’Imagerie Biomédicale (FR)
- Pitié-Salpêtrière Hospital (FR)
- Groupe de recherche clinique – Tumeurs Thyroïdiennes
Publication Details
- Journal
- European Thyroid Journal
- Published
- 2024-12-04
- DOI
- https://doi.org/10.1530/etj-24-0160
- Citations
- 2
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.72